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Abstract
Injury to the skin provides a new challenge, as wound healing is a complex and intricate process. Nonhealing wounds represent a
significant cause of morbidity and mortality for a large portion of the population. Delayed wound healing is one of the major ther-
apeutic and economic issues in medicine today. Wound healing requires a concerted effort of remodeling of various components
of the connective tissue in the presence of appropriate cytokines and growth factors. Unfortunately we still do not understand the
actual mechanism of wound healing. This review is an effort to provide information about current challenges of wound healing and
their management, recent advances in wound care technology and current management guidelines for the treatment of wounds
and ulcers. Various steps like microbial control, subsidence of inflammation, regeneration of connective tissue, angiogenesis and
epithelialisation should take place in a time-bound sequence. The development of new and effective interventions in Wound care
remains an area of intense research
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Introduction
Wound healing is a highly dynamic process and involves com-
plex interactions of extracellular matrix molecules, soluble me-
diators, various resident cells, and infiltrating leukocyte sub-
types [1]. Wound-healing process consists of four highly inte-
grated and overlapping phases: homeostasis, inflammation, cell
proliferation, and lesion contraction or tissue remodeling [2].
There are many factors that can affect wound healing. Wound
healing a matter of concern even with advance therapies [3].
There are many factors that can affect wound healing which in-
terfere with one or more phases in this process, thus causing
improper or impaired tissue repair [4]. Currently, there are var-
ious challenges in wound healing such as antibiotics resistance,
different wound healing rate and wound healing abilities of pa-
tients.
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Epidemiology of wound healing
According to the Wound Healing Society, about 15% of older
adults in the US suffer from chronic wounds, including pre-
dominantly venous stasis ulcers, pressure ulcers (bedsores), and
diabetic (neuropathic) foot ulcers. Every year 2 to 3 million
more Americans are diagnosed with various types of chronic
wounds [5, 6]. Most of the ulcers in India are undoubtedly due to
venous etiology, but many other causes such as filariasis, tuber-
culosis, and leprosy, not frequently seen in the western countries,
add to the misery of the Indian patient. The study from India
shows that etiology of chronic wounds included systemic con-
ditions such as diabetes and atherosclerosis. Other major causes
included pressure ulcers, vasculitis, and trauma [7]. There are
few Indian studies on the epidemiology of chronic wounds, one
study estimated the prevalence at 4.5/1000 population while, the
incidence of acute wounds was more than double at 10.5/1000
population [8, 9].
Categories of wounds
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Figure 1 Flow diagram of chronic wound management. Chronic wound are classifiedinto three categories (green box): venous leg ulcers (VLUs),
diabetic footulcers (DFUs) and pressure ulcers (PSUs). Further in (grey boxes) chronicwounds are classified into subcategories based on their
suspected etiology. Atearlier stages all wounds are assumed to be ‘easy’ to treat and receive theappropriate care such as ‘offloading’, antibiotics
and surgery. Consequently,if healing failed, wounds get gradually more aggressive treatment, such asdebridement and biological intervention. If all
treatments fail, thenamputation takes place .
Different Phases of Wound Healing
Inflammatory phase
Inflammatory phase is the initial phase after cutaneous injury is
dominated by inflammatory reactions mediated by growth fac-
tors, cytokines, chemokines and their actions on cellular recep-
tors. At this phase Intracellular signaling cascades are activated,
contributing to cell proliferation, migration, and differentiation.
During the inflammatory phase of wound healing, a variety of
membrane-bound receptors play a role in recruiting leukocytes
and other cells [10, 11]. The product used in inflammatory phase
is Promogran, containing growth factors such as (G-CSF, TGF-
β1 and β2).
Proliferative phase
The Proliferative phase has three stages such as neoangiogene-
sis, formation of granulation tissue and re-epithelialization. At
neoangiogenesis stage macrophages rediscovered in their in-
teraction with fibroblasts [12]. In the proliferative phase nutri-
ents and oxygen are limiting factors because of the tremendous
metabolic activity. A number of other relevant factors important
for fibroblast proliferation in cutaneous wound healing such as
extracellular matrix (ECM) and secreted protein acidic and rich
in cysteine (SPARC) [13]. The products which are useful at the
2nd stage of wound healing are Dermagraft, TransCyte, Allo-
derm, Apligraf, OrCel containing platelets derived growth factor
(PDGF), fibroblast growth factor, (FGF) and vascular endothe-
lial growth factor VEGF.
Re-epithelization phase
In this stage covering the wound surface occurs with a layer of
epithelium which is based on the differentiation, proliferation,
and migration of epidermal keratinocytes [14]. After the wound
bed has been properly established with proliferating fibroblasts,
a new collagen matrix and the process of re-epithelialization
start [15]. The products which are helpful to treat the wound at
this stage are Epicel, Laserskin, CellSpray, BioSeed-S, Lypho-
Derm, and Trancell combination of different growth factor such
as epidermal growth factor (EGF), keratinocytes growth factor
(KGF) and granulocyte macrophage colony stimulating factor
(GM-CSF).
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Remodeling and scarring phase
This phase starts as early as a few days after injury and lasts
up to 2-2.5 years. In this phase, a variety of proteinases such
as matrix metalloproteinase (MMP), tissue inhibitor of matrix
metalloproteinase (TIMP) contribute to wound healing [16, 17].
The (MMPs) play a central role in wound healing since they de-
grade certain constitutes of interim wound tissue, such as colla-
gen I, III, IV, and VII [18]. MMP2 (gelatinase 2) has been proved
an important factor for targeting of angiogenesis, inflammation,
and fibrosis in wound healing [19]. The currently useful prod-
ucts in the treatment of wound at this stage is Silicone based
products, such as silicone gel sheet (Cica-care) based on trans-
forming growth factor (TGF-3).
Challenges in the Treatment of
Wound Healing
Wound healing involves growth factors, oxygen accessibility,
substrates and a suitable healing environment. During wound
healing process most of these factors are assumed to be present
and contributes a great role in wound healing. There are some
major challenges related to treatment of wound such as re-
currence of wound after treatment (fore foot malperforans ul-
cer), [20] patients’ wound healing abilities and potential, varia-
tion in wound treatment, rate of wound healing, infection influ-
ence on healing process, weak angiogenesis system, role of Im-
mune system and antibiotics resistance etc. [21]. But now there
is one concern is towards appropriate environment through ther-
apeutic agents and debridement to heal the wound [22].
Role of angiogenesis system
New blood vessel formation is a critical component of wound
healing. During wound healing, angiogenic capillary sprouts in-
vade the fibrin/fibbronectin-rich wound clot and within few days
organize into a micro vascular network throughout the granu-
lation tissue. As collagen accumulates in the granulation tissue
to produce scar, the density of blood vessels diminishes [23].
A dynamic interaction occurs among endothelial cells and an-
giogenic stimulating factors leading to morphogenetic changes
in blood vessels during wound repair. There are various angio-
genesis stimulating factors such as fibroblast growth factors i.e.
acidic fibroblast growth factors and basic fibroblast growth fac-
tors, vascular endothelial growth factors (VEGFs), human mast
cell tryptase [24], angiogenin and angiopiotin. (VEGF), and
platelets derived growth factors (PDGF) etc. Besides the growth
factors and chemo tactic factors an appropriate extracellular ma-
trix (ECM) is also equally helpful in angiogenesis [25].
Antibiotics resistance
Antimicrobial resistance is now a global threat. Bacterial resis-
tance to antibiotics is becoming a major challenge in all parts of
the world with the impact on the practice of medicine being seen
most acutely [26]. The achievements of modern medicine are put
at risk by antimicrobial resistance. The overuse and misuse of
antimicrobial drugs accelerates the emergence of drug-resistant
strains. Antibiotic-resistant bacteria (Streptococcus pneumoniae,
S. aureus, Gram-negative bacteria such as Pseudomonas aerug-
inosa and Acinetobacter baumannii, bacteria in diabetic foot in-
fection) represent an increasing concern in wound infections.
Wound colonization with these organisms normally results in
aggressive management of the wound complicated by a greatly
limited choice of therapeutic antibiotics [27]. Wound infection
with antibiotic-resistant bacteria may cause further morbidity in
the patient and result in additional treatment costs as a result of
measures being instituted to reduce patient-to-patient transmis-
sion and control nosocomial outbreaks in the ward or institu-
tion [28].
Role of immune system
Immune cells have an integral function in wound healing be-
yond their role in inflammation and host defense. Immune cells
are vital to the regulation of the wound-healing process through
the secretion of signaling molecules, such as cytokines, lym-
phokines, and growth factors [29]. The immune system is di-
vided into two defense arms i.e. humoral and cellular. Humoral
arms comprises competence and antibodies leading to wound
healing while cellular arm comprises three defense arm such
as neutrophils, macrophages and lymphocytes [30]. Neutrophils
are the first immune cells that reach the wound site and helps
to reduce the infection whereas macrophages plays critical and
important role in wound healing. The antimicrobial function of
macrophages is carried out by phagocytosis and generation of re-
active radicals such as peroxides, oxygen and nitric oxides [31].
The main role of macrophages in wound healing is secretion of
growth factors and cytokines that leads to proliferation and col-
lagen synthesis [32].
Influence of infection
Wound infection is a complex process that results from a detri-
mental interaction between the patient and the pathogen(s) that
can delay healing and cause wound pain [33]. Wound infection is
one of the most challenging aspects of wound management and
a major contributor to healthcare costs globally [34]. The main
underlying cause of infection related wound pain is the inflam-
matory response stimulated by the infecting microorganisms.
This response causes the release of inflammatory mediators and
stimulates the production of enzymes and free radicals, which
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can cause tissue damage. Further indicators of wound infection
that may impact on comfort and, by causing distress, contribute
to pain include: friable granulation tissue that bleeds easily; in-
creased exudate production; abnormal smell; and wound break-
down [35]. In particular, wound exudate produced in response
to colonization or local infection of a wound may contribute to
wound pain. Chronic wound exudate contains increased levels
of free radicals and numerous enzymes, such as matrix metallo-
proteinase (MMPs), that can damage healthy wound tissue and
may be harmful to the surrounding skin [36]. It is important to
determine at which point critical colonization has been reached
or the level at which the type and quantity of bacteria begin to
cause active infection.. Surrounding erythema, swelling, indura-
tion, tenderness, and malodor are the expected characteristics of
an infected wound [37].
Management of Wound Healing
Management of wound is a multidisciplinary approach. It in-
volves the following aspects. The initial step in the manage-
ment of any wound is to remove the local impediments to wound
healing by eliminating devascularized tissue, necrotic material,
and excessive bacterial burden [38, 39]. Modern wound dressing
preparation strategies involve a thorough and yet judicious de-
bridement, preserving vital tissue while ridding the wound site
of the accumulated impediments to optimal healing. At present,
numerous modalities are available for debriding wounds such
as Tissue engineering substitutes, various types of antiseptics
products, various non surgical approaches and different types of
wound dressings [40].
Mechanical and current therapy in the treatment of
wounds
Topical treatments and dressings are essential for the manage-
ment of wound exudate, and can be used to promote a moist
environment. In addition to moisture, adequate tissue blood flow
and oxygen levels are required for healing, and to avoid infec-
tion and further tissue damage. All these therapies are associated
with significant expense and are being utilized in some situa-
tions without sufficient scientific evidence demonstrating their
efficacy. Therefore, the search for an efficacious, convenient and
cost-effective therapy continues.
Radiant heat dressing
The use of heat in wound healing has been demonstrated to
aid oxygen flow and hence healing in acute wounds. Control of
ambient temperature or application of heat locally may benefit
healing and, in particular, increase patients’ resistance to infec-
tion [41]. In acute wound condition reductions in body temper-
ature during and following surgery elicit thermoregulatory re-
sponses that include cutaneous vasoconstriction, evidenced by
low tissue-oxygen levels and a delay in the return to normal lev-
els [42, 43].
Hyperbaric oxygen therapy (HBOT)
This therapy is occasionally used as an adjunct to standard
wound care. HBOT, which involves breathing 100% oxygen
at supra-atmospheric pressures while inside of a compression
chamber, is based on the rationale that tissue hypoxia contributes
to the failure of many chronic wounds to heal [44]. HBOT ap-
pears to decrease the rate of major amputation related to diabetic
foot ulcers and may improve the chance of diabetic foot ulcer
healing at 1 year [45]. HBOT is associated with several potential
adverse effects, including oxygen toxicity to brain and lung as
well as barotraumas to the ears, lungs, and sinuses. In addition,
temporary myopia is a very common adverse effect [44].
Negative pressure wound therapy (NPWT)
Negative Pressure Wound Therapy (NPWT) is a newer nonin-
vasive adjunctive therapy system that uses controlled negative
pressure using Vacuum-Assisted Closure device (VAC) to help
promote wound healing by removing fluid from open wounds
through a sealed dressing and tubing which is connected to a col-
lection container. The role of negative pressure dressing in heal-
ing of diabetic foot ulcers has been proposed as a novel method
of manipulating the chronic wound environment in a way that
it reduces bacterial burden and chronic interstitial wound fluid,
increases vascularity and cytokine expression and to an extent
mechanically exploiting the viscoelasticity of peri wound tis-
sues [46]. Application of negative pressure over wound bed al-
lows the arterioles to dilate, so increasing the effectiveness of
local circulation, promoting angiogenesis, which assists in the
proliferation of granulation tissue [47, 48].
Topical oxygen therapy
Oxygen supply for chronic non-healing wounds has recently
been a focus of interest for many investigators. The partial pres-
sure of oxygen (pO2) is a key factor in wound healing and the
literature has consistently reported that a transcutaneous (pO2)
below 40 mm Hg is strongly associated with poor wound heal-
ing [49]. While increasing pO2 at the wound edge improves hy-
poxia, it also promotes several other aspects of wound healing
through the production of reactive oxygen species (ROS). Re-
cent evidence, indeed, revealed that oxygen is not merely the
primary source of energy, but also generates several ROS which
may function as intracellular messengers in normal cell signal
transduction and cell cycling. During wound healing the pres-
ence of oxygen takes on additional importance because of the
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increased demand of reparative processes like cell proliferation
and synthesis of collagen [50, 51].
Gauze
Gauze is a thin, translucent fabric with a loose open weave. It
is historically been one of the most popular wound dressing [52]
Being inexpensive, it is still the most commonly used dressing in
hospitals. These dressings are available in both pad and ribbon
form. Gauze ribbons are ideal for treating deep wounds and sinus
tracts, which heal from the base upwards in order to eliminate
dead space and prevent abscess formation [53]. Loose packing
with gauze ribbons encourages healing from the base outward.
Packing should never be tight, because this may cause localized
ischemia and wound enlargement. Some marketed gauzes are
given in (Table 1). [54]
Table 1 Different type of marketed gauzes
Mesalt Hypertonic sodium chloride-impregnated
gauze.
Highly absorbent
Mo
Inlycke
Xeroform Less adherent than plain gauze Kendall
Vaseline
gauzes
Gauze impregnated with petrolatum, less
adherent than plain gauze
Kendall
Films
Films are transparent, conformable, adhesive dressings that may
be used as primary dressings directly over a wound. Film dress-
ings are non absorbent; they manage moisture by vapor trans-
mission only [54]. So, films should be reserved for wounds with
minimal exudate. Films are used inappropriately over a wound
with heavy exudate; they may cause fluid trapping and macer-
ation [55] There is been a tendency to strip delicate new epi-
dermis from newly re-epithelialized areas of a healing wound
if films are applied and removed too frequently [56]me markets
films and their products are given below in (Table 2).
Table 2 Films and their products
Blister film Adhesive-free wound contact area Kendall
OpSite
Flexi grid
Printed with wound measurement grid
to track healing
Smith &
Nephew
Bioclusive Classic film dressing J & J
Hydrogels
Hydrogels are debriding agents used in the management of
wounds. They are water-based products used to maintain a
moist wound-healing environment. They are best suited for dry
wounds or wounds with low levels of exudate, and should be
avoided in wounds with heavy exudate because the excess mois-
ture can lead to maceration of periwound skin [57, 58] Hydro-
gels are available in two forms, amorphous and sheet hydrogel.
Amorphous hydrogel are soft formless gel that become less vis-
cous as they absorb fluid, while sheet hydrogels are firm sheets
of gel that swell when fluid is absorbed. Hydrogel also pro-
mote autolytic debridement of slough and necrotic tissue, mak-
ing them suitable debriding agents in patients for whom sharp
debridement is contraindicated [58] key advantage of hydrogels
is that they can be applied and removed with minimal pain or
trauma to the wound bed. Several small studies have shown Hy-
drogels to perform similarly to moist gauze and hydrocolloid
dressings in rate of pressure ulcer healing [59, 60]. Some of the
marketed hydrogels and their products are given in (Table 3).
Table 3 Hydrogels and their products
X cell cellulose
dressing
Moisture-retentive No traumatic
removal Pain relief
Xylos
Carrasyn Amorphous gel, contains aloe Vera
gel extract
Car-
rington
Hydrocolloids
Hydrocolloids in contrast to the fluid-donating Hydrogel, pro-
vides absorption. They are used over wounds with low to moder-
ate amounts of exudate. These adhesive, occlusive, conformable
dressings absorb wound exudate to forma hydrophilic gel that
helps to maintain a moist healing environment [61, 62]. A major
advantage of hydrocolloid dressings that it can protect against
shear force at the skin surface, which is a contributor to pressure
ulcer development [63] me hydro colloidal marketed prepara-
tions are in (Table 4).
Table 4 Hydrocolloids and their products [64]
Tegasorb Transparency after use. 3M
Comfeel
Plus
Contains alginate for increased
absorption
Colo-
plast
Alginates
Alginates made from brown seaweed are highly absorbent, fi-
brous dressings that can hold up to 20 times their weight in
fluid [65]. Alginate dressings are utilized mainly for their strong
absorptive capacity on wounds with moderate to heavy levels of
exudat [66, 67]. It is important that these very absorptive dress-
ings be kept from desiccating over the wound; because the resul-
tant dry environment could delay wound haling [57]. A unique
advantage of alginate dressings is that they are inherently haeo-
static [68, 69] and can be used to control minor bleeding.
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Table 5 Alginates and their products
Aquacel Hydro
fiber
More absorptive than
alginates
ConvaTec
Kaltostat High guluronic acid content ConvaTec
Sorbsan High mannuronic acid
content
Bertek
AlgiSite High mannuronic acid
content
Smith &
Nephew
Foams
Foams are moderately absorbent, semi occlusive dressings that
may be used over light to moderately draining wounds. They
are made from semi permeable polyurethane and used for their
cushioning effect as the dressings allow water vapor to enter but
keep out bacteria and other contaminants though they are not in-
tended as a substitute for proper pressure-relieving devices [70].
The fluid absorption capacity of these dressing varies with foam
thicknes [71]. Some foam has a film backing to prevent exudates
leakage and to provide an additional barrier to bacterial contam-
inaion.
Currently available antiseptics
products for treating wound
Quality care is a critical requirement for wound healing and
’good’ care of wounds has been synonymous with topical pre-
vention and management of microbial contamination. Topical
antiseptics are antimicrobial agents that kill, inhibit or reduce
the number of microorganisms and are thought to be essential
for wounds infection control. However, they have long and com-
monly been used on wounds to prevent or treat infection. Re-
peated and excessive treatment of wounds with antiseptics with-
out proper indications may promote a microenvironment similar
to those found in chronic wounds. However, when applied at
the proper times and concentrations, some classes of antiseptics
may provide a tool for the clinician to drive the wound bed in
desired directions. There are list of antiseptics which are useful
in treatment of wound in (Table 7) [71–74]
Biological Products for different
phases of wound healing
Chronic wounds may be arrested in any of the four phases; com-
monly, however, disruption occurs in the inflammatory or the
proliferative phases. Many mediators—including inflammatory
cells, growth factors, proteases such as matrix metalloproteinase
(MMPs), and cellular and extracellular elements—play impor-
tant roles in different stages of the healing process. Alterations
in one or more of these components may account for the im-
paired healing observed in chronic wounds. More recently, ar-
tificial growth factors such as G-CSF, TGF-β1 and β2, PDGF,
FGF, and VEGF etc. have been developed to help achieve heal-
ing in chronic, non-healing wounds of varying aetiologies [75]
in (Table 8).
Tissue engineering substitutes in
wound healing
Since long time human amniotic membrane and frog skin have
long been used to treat burn wounds. Recently growth factors
and artificial “skin substitutes” have been developed to achieve
healing in chronic and non-healing wounds. These following ar-
tificial skin substitutes consist of a micro engineered, biocom-
patible, polymer matrix in combination with cellular or extracel-
lular elements such as collagen. Followings are the tissue engi-
neered skin substitutes in wound healing in (Table 9) [76]
Conclusion
In this review, we have discussed various current aspects
and therapies for wound healing. Wound healing is a com-
plex biological process that consists of homeostasis, inflam-
mation, proliferation, and remodeling. Large numbers of cell
types—including neutrophils, macrophages, lymphocytes, ker-
atinocytes, fibroblasts, and endothelial cells— are involved in
this process. Recent studies identified the crucial role of several
growth factors, various types of physico – mechanic therapies
besides antimicrobial / antibiotics. Complex wounds represent
a major challenge for the clinician and wound care specialist.
Despite, all the recent advances in wound care therapies and
our understanding of the pathophysiology of chronic wounds;
nothing can supplant the need for adhering to the basic tenets of
wound care. Medical and nutritional optimization, debridement
(including surgery), management of ischemia, management of
infection, offloading (or compression), and appropriate wound
bed preparation are the current practices followed but there is
no uniform protocol. We discussed many current therapies for
wound healing but recurrence of wound raise a question on
these current therapies. Regulating the activity of cells involved
in wound healing seems to be a hot topic in future wound ther-
apy as many new and interesting factors are being discovered.
Hence, chronic wounds represent such a profound, unsolved,
and rapidly increasing health problem with exuberant morbidity,
mortality and cost. There is a need to explore the application of
current therapies to enhance the success rate of wound healing.
We believe that this area of research may continue to be fruitful
for many researchers to develop various treatments for wound
healing.
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Table 6 Foam dressings [72]
Allevyn hydro cellular
dressing
Trilaminate structure with nonadherent wound contact layer, absorbent central layer, and semi
permeable film outer layer
Smith
&Nephew
Allevyn cavity dressing Absorbent foam chips covered with nonadherent wound contact layer) Smith
&Nephew
Lyofoam C Contains activated carbon for odor control ConvaTec
Table 7 Sliver dressings
Products Company Formulation Advantages Disadvantages
Aquacel Ag Hydro
fiber
ConvaTec Silver impregnated hydro fiber dressing Slow release of
silver ions
Levels of silver ions at wound
interface not
well defined [71]
Contreet Foam Coloplast Rapid release of silver ions. Less painful May delay epithelialization [72]
Silverlon wound
Contact dressing
Argentum Silver-coated wound contact layer, absorbent pad,
and film backing Silver-containing hydrogel
Few adverse effects
than silver nitrate
Relatively expensive
Silvasorb Medline Relatively low silver content Microbial resistance
is rare
May cause silver staining of
Tissues
Silvercel Johnson &
Johnson
Coated with nanocrystalline silver Microbial resistance
is rare
May cause silver staining of
Tissues [73]
Acticoat 7 Smith &
Nephew
Rapid release of silver ions Less painful Rapid release of silver ions[74]
Table 8 G-CSF - granulocyte colony stimulating factor, TGF- β1 and β2 transforminggrowth factor, PDGF - platelet derived growth factor; FGF -
fibroblast growthfactor; VEGF - vascular endothelial growth factor; EGF - epidermal growthfactor; KGF- keratinocytes growthfactor; GM-CSF -
granulocyte macrophage colony stimulating factor; TGF- transforming growth factor [76].
Sr.No Phase Products Growth factors
1 Inflammatory phase Promogran G-CSF, TGF-β1 and β2
2 Proliferative phase Dermagraft, TransCyte, Alloderm, Apligraf, OrCel PDGF, FGF, VEGF
3 Epithelialisation Epicel, Laserskin, CellSpray, BioSeed-S, LyphoDerm, Trancell EGF, KGF, GM-CSF
4 Remodeling and scarring Silicone based products, such as silicone gel sheet (Cica-care) TGF-3
Table 9 Tissue engineered skin substitutes in wound healing.*Epidermal; †Dermal,a cellular; ‡Dermal, cellular; §Composite [75, 76].
Products Advantages Disadvantages
Integra† Immediate permanent coverage for reconstructive surgery Autograft is needed after 3-4 weeks for epithelial cover
TransCyte‡ To coat surgically excised full thickness burns and non-excised
limited thickness burns
Not appropriate for infected wounds and patients who are
allergic to porcine collagen
Epicel,
Laserskin*
Permanent coverage for superficial and partial thickness burns 2-3 week lag phase between biopsy and obtaining epidermis
AlloDerm† permanently cover full thickness burns and deep ulcers Autograft is required for epithelial cover and not appropriate for
infected wounds
Apligraf§ Chronic wounds such as diabetic foot ulcer and venous leg
ulcer
Not for patients allergic to bovine collagen
OrCel§ Acute and chronic deep dermal ulcers, partial thickness burns Not for infected wounds or patients allergic to bovine collagen
Biobrane† To coat widespread partial thickness burns and donor sites suitable for infected burn wounds
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